Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age

J. Claire Bramley; Timothy Hall; Adam Finn; Roger B. Buttery; David Elliman; Stephen Lockhart; Raymond Borrow; Ian G. Jones

doi:10.1016/S0264-410X(00)00528-4

Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age

J. Claire Bramley, Timothy Hall, Adam Finn, Roger B. Buttery, David Elliman, Stephen Lockhart, Raymond Borrow, Ian G. Jones

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

The reactogenicity and immunogenicity of meningococcal serogroup C conjugate (MenC) vaccine was assessed in 322 infants vaccinated at 2, 3, and 4 months of age, with concomitant administration of mixed diphtheria-tetanus-whole-cell pertussis vaccine and Haemophilus influenzae type b conjugate vaccine (DTwP-Hib) and oral polio vaccine. All infants in whom post-vaccination meningococcal C anticapsular IgG levels were assayed (n = 265) attained ≥ 2 μg ml^-1. Serum bactericidal titres were assayed for a proportion of subjects (n = 171), 98% of whom obtained a reciprocal titres ≥ 8. Local reactions were less frequent at the MenC injection site than at the DTP-Hib site. Systemic events were frequent, but consistent with established DTwP-Hib experience. The study demonstrates that MenC vaccine is immunogenic and well tolerated in infants at manufacturing scale production levels.

Original language	English
Pages (from-to)	2924-2931
Number of pages	8
Journal	Vaccine
Volume	19
Issue number	20-22
DOIs	https://doi.org/10.1016/S0264-410X(00)00528-4
Publication status	Published - 6 Apr 2001
Externally published	Yes

Bibliographical note

Funding Information:
This trial was supported by a grant from Wyeth-Lederle Vaccines and Pediatrics. We gratefully acknowledge the support of the following for their invaluable help in conducting this trial. Statistical analysis was performed by Dominique Rosillon of Biopharma, Wavre, Belgium. The following contributed at the sites: Cornwall Clinical Research Group (Drs Butler, Cook, Fletcher, Gillespie, Golding-Cook, Jones, Rotheray, Thomas); Suffolk (Drs Arthur, Dunne, Kemp, Leeper and Selby); Scotland (Geraldine Allan, Elizabeth Drummond, Drs Aitken, Carlyle, Carr, Heeles, Hyndman, Krishnaswamy and Wallace, Sharon Hutchinson); Sheffield (Dr Sharon Choo, Roger Burkinshaw); London (Gail Balfour); Specialist Monitoring Services Ltd, Crowthorne, Berkshire, England (Caroline Dunn, Julie Greenfield); Manchester Public Health Laboratory (Sarah Martin, Jamie Findlow).

Keywords

Conjugate vaccine
Polysaccharide
Serogroup C meningococcus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(00)00528-4

Cite this

@article{6e3c9f106b464bb6aed4fe0117f3dcfa,

title = "Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age",

abstract = "The reactogenicity and immunogenicity of meningococcal serogroup C conjugate (MenC) vaccine was assessed in 322 infants vaccinated at 2, 3, and 4 months of age, with concomitant administration of mixed diphtheria-tetanus-whole-cell pertussis vaccine and Haemophilus influenzae type b conjugate vaccine (DTwP-Hib) and oral polio vaccine. All infants in whom post-vaccination meningococcal C anticapsular IgG levels were assayed (n = 265) attained ≥ 2 μg ml-1. Serum bactericidal titres were assayed for a proportion of subjects (n = 171), 98% of whom obtained a reciprocal titres ≥ 8. Local reactions were less frequent at the MenC injection site than at the DTP-Hib site. Systemic events were frequent, but consistent with established DTwP-Hib experience. The study demonstrates that MenC vaccine is immunogenic and well tolerated in infants at manufacturing scale production levels.",

keywords = "Conjugate vaccine, Polysaccharide, Serogroup C meningococcus",

author = "Bramley, {J. Claire} and Timothy Hall and Adam Finn and Buttery, {Roger B.} and David Elliman and Stephen Lockhart and Raymond Borrow and Jones, {Ian G.}",

note = "Funding Information: This trial was supported by a grant from Wyeth-Lederle Vaccines and Pediatrics. We gratefully acknowledge the support of the following for their invaluable help in conducting this trial. Statistical analysis was performed by Dominique Rosillon of Biopharma, Wavre, Belgium. The following contributed at the sites: Cornwall Clinical Research Group (Drs Butler, Cook, Fletcher, Gillespie, Golding-Cook, Jones, Rotheray, Thomas); Suffolk (Drs Arthur, Dunne, Kemp, Leeper and Selby); Scotland (Geraldine Allan, Elizabeth Drummond, Drs Aitken, Carlyle, Carr, Heeles, Hyndman, Krishnaswamy and Wallace, Sharon Hutchinson); Sheffield (Dr Sharon Choo, Roger Burkinshaw); London (Gail Balfour); Specialist Monitoring Services Ltd, Crowthorne, Berkshire, England (Caroline Dunn, Julie Greenfield); Manchester Public Health Laboratory (Sarah Martin, Jamie Findlow). ",

year = "2001",

month = apr,

day = "6",

doi = "10.1016/S0264-410X(00)00528-4",

language = "English",

volume = "19",

pages = "2924--2931",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "20-22",

}

TY - JOUR

T1 - Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age

AU - Bramley, J. Claire

AU - Hall, Timothy

AU - Finn, Adam

AU - Buttery, Roger B.

AU - Elliman, David

AU - Lockhart, Stephen

AU - Borrow, Raymond

AU - Jones, Ian G.

N1 - Funding Information: This trial was supported by a grant from Wyeth-Lederle Vaccines and Pediatrics. We gratefully acknowledge the support of the following for their invaluable help in conducting this trial. Statistical analysis was performed by Dominique Rosillon of Biopharma, Wavre, Belgium. The following contributed at the sites: Cornwall Clinical Research Group (Drs Butler, Cook, Fletcher, Gillespie, Golding-Cook, Jones, Rotheray, Thomas); Suffolk (Drs Arthur, Dunne, Kemp, Leeper and Selby); Scotland (Geraldine Allan, Elizabeth Drummond, Drs Aitken, Carlyle, Carr, Heeles, Hyndman, Krishnaswamy and Wallace, Sharon Hutchinson); Sheffield (Dr Sharon Choo, Roger Burkinshaw); London (Gail Balfour); Specialist Monitoring Services Ltd, Crowthorne, Berkshire, England (Caroline Dunn, Julie Greenfield); Manchester Public Health Laboratory (Sarah Martin, Jamie Findlow).

PY - 2001/4/6

Y1 - 2001/4/6

N2 - The reactogenicity and immunogenicity of meningococcal serogroup C conjugate (MenC) vaccine was assessed in 322 infants vaccinated at 2, 3, and 4 months of age, with concomitant administration of mixed diphtheria-tetanus-whole-cell pertussis vaccine and Haemophilus influenzae type b conjugate vaccine (DTwP-Hib) and oral polio vaccine. All infants in whom post-vaccination meningococcal C anticapsular IgG levels were assayed (n = 265) attained ≥ 2 μg ml-1. Serum bactericidal titres were assayed for a proportion of subjects (n = 171), 98% of whom obtained a reciprocal titres ≥ 8. Local reactions were less frequent at the MenC injection site than at the DTP-Hib site. Systemic events were frequent, but consistent with established DTwP-Hib experience. The study demonstrates that MenC vaccine is immunogenic and well tolerated in infants at manufacturing scale production levels.

AB - The reactogenicity and immunogenicity of meningococcal serogroup C conjugate (MenC) vaccine was assessed in 322 infants vaccinated at 2, 3, and 4 months of age, with concomitant administration of mixed diphtheria-tetanus-whole-cell pertussis vaccine and Haemophilus influenzae type b conjugate vaccine (DTwP-Hib) and oral polio vaccine. All infants in whom post-vaccination meningococcal C anticapsular IgG levels were assayed (n = 265) attained ≥ 2 μg ml-1. Serum bactericidal titres were assayed for a proportion of subjects (n = 171), 98% of whom obtained a reciprocal titres ≥ 8. Local reactions were less frequent at the MenC injection site than at the DTP-Hib site. Systemic events were frequent, but consistent with established DTwP-Hib experience. The study demonstrates that MenC vaccine is immunogenic and well tolerated in infants at manufacturing scale production levels.

KW - Conjugate vaccine

KW - Polysaccharide

KW - Serogroup C meningococcus

UR - http://www.scopus.com/inward/record.url?scp=0035815489&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(00)00528-4

DO - 10.1016/S0264-410X(00)00528-4

M3 - Article

C2 - 11282204

AN - SCOPUS:0035815489

SN - 0264-410X

VL - 19

SP - 2924

EP - 2931

JO - Vaccine

JF - Vaccine

IS - 20-22

ER -

Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this